Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Mink Intersects 7.1 Meters of 0.44% Ni, 0.28% Cu, 0.06% Co in Massive Sulphide at Warren Property (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Enzon Inc (QB) ENZN

Healthcare Biotechnology
Enzon Pharmaceuticals, Inc. does not have significant operations. Previously, it was engaged in the sale of its drug product, PegIntron. The company was formerly known as Enzon, Inc and changed its name to Enzon Pharmaceuticals, Inc. in December 2002. Enzon Pharmaceuticals, Inc. was incorporated in 1981 and is headquartered in Cranford, New Jersey.

Recent & Breaking News (OTCQB:ENZN)

    Enzon Announces Extension of Exchange Offer Relating to Series C Non-Convertible Redeemable Preferred Stock

    GlobeNewswire 3 hours ago

    Enzon Announces Extension of Exchange Offer Relating to Series C Non-Convertible Redeemable Preferred Stock

    GlobeNewswire 1 day ago

    Enzon Announces Extension of Exchange Offer Relating to Series C Non-Convertible Redeemable Preferred Stock

    GlobeNewswire 12 days ago

    Enzon Announces Commencement of Exchange Offer Relating to Series C Non-Convertible Redeemable Preferred Stock in Connection With Viskase Merger

    GlobeNewswire January 30, 2026

    Enzon and Viskase Announce Amendment to Merger Agreement

    GlobeNewswire October 24, 2025

    Enzon and Viskase Enter into Merger Agreement

    GlobeNewswire June 20, 2025

    Enzon Pharmaceuticals, Inc. CEO Andrew Rackear to Retire; Richard L. Feinstein, Enzon's CFO, to Assume Position of CEO and Remain CFO

    GlobeNewswire January 4, 2021

    Enzon Pharmaceuticals Announces Results of Rights Offering

    GlobeNewswire October 21, 2020

    Enzon Pharmaceuticals Announces Key Dates for Rights Offering

    GlobeNewswire September 15, 2020

    Enzon Pharmaceuticals, Inc. Announces Postponement of 2020 Annual Meeting

    GlobeNewswire September 2, 2020

    Enzon Pharmaceuticals Anticipated Rights Offering to Existing Shareholders

    GlobeNewswire August 21, 2020

    Enzon Pharmaceuticals, Inc. Adopts Tax Benefits Preservation Plan to Protect its NOL Assets and Shareholder Value

    GlobeNewswire August 14, 2020

    Icahn's (Potential) Move Into Biotech

    Benzinga.com  March 4, 2017

    SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Breaches of Delaware Law by the Board of Enzon Pharmaceuticals Inc.

    PR Newswire January 27, 2016

    Guidance & Quarterly Review on Four Biotech Companies

    ACCESS Newswire August 14, 2015

    Enzon Adopts Stockholder Rights Plan in an Effort to Protect Net Operating Loss Carryforwards

    Business Wire May 1, 2014

    TrendingWallStreet.com Begins Trend Analysis on ABX, ENZN, DEWM, and ORMP

    ACCESS Newswire December 26, 2013

    Free Research Reports on ENZN, FSLR, IRBT and MTH Issued by the Bedford Report

    Marketwired April 26, 2013

    Enzon Concludes Review of Possible Asset Sales, Sale of the Company; Announces $1.60 Special Dividend and Periodic Royalty Dividends

    Marketwired April 23, 2013

    Enzon Reports Fourth Quarter and Full Year 2012 Results

    Marketwired March 18, 2013

      Podcasts